The researchers noted that compared with the control group, the epithalamin-treated patients exhibited [10]: Decelerated aging of the cardiovascular system Decreased rate of cardiovascular mortality and cardiovascular failure (-50%) Less age-associated impairment of physical endurance Normalized circadian rhythm for melatonin production Normalized circadian rhythm for lipid (fats) and carbohydrate metabolism Lower rate of mortality (-28%) The follow-up study on long-term epithalamin treatment represents strong evidence of eptithalons favorable safety profile and relative absence of notable epithalon side effects
Most research write-ups describe a single evening subcutaneous research-use dose 1-3 hours before intended sleep
0.6% acetic acid solution Required for certain peptides like IGF-1 LR3, IGF-1 DES, and NAD+ that degrade in both bacteriostatic and sterile water
[DOI] [PubMed] [Google Scholar] Noshi M, Hatanaka R, Tanabe N, Terai Y, Maruta T, Shigeoka S
Understanding these interactions remains an important focus of laboratory research, with BPC-157 continuing to feature in studies exploring molecular signalling, tissue architecture and physiological regulation
